Loading clinical trials...

Kidney Precision Medicine Project | Clinical Trials | Clareo Health

RECRUITINGNCT04334707

Kidney Precision Medicine Project

Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Despit...

Lead sponsor: University of Washington•8 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Ashveena Dighe, MS, MPH

CONTACT

206-744-4029 ashveena@nephrology.washington.edu

Kristina Blank, MPH

CONTACT

206-897-1957 blankk@uw.edu

Sponsors

Lead Sponsor

University of Washington

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Michigan
Icahn School of Medicine at Mount Sinai
Brigham and Women's Hospital
Broad Institute of MIT and Harvard
The Cleveland Clinic
Columbia University
European Molecular Biology Laboratory
Indiana University
Johns Hopkins University
Joslin Diabetes Center
Pacific Northwest National Laboratory
Princeton University
Stanford University
Ohio State University
University of California, San Diego
University of California, San Francisco
University of Pittsburgh
The University of Texas Health Science Center at San Antonio
University of Texas
Washington University School of Medicine
Yale University

The Kidney Precision Medicine Project (KPMP) is a prospective cohort study, whose goal is to use deep molecular phenotypes of kidney biopsies, along with longitudinally collected clinical phenotypic data, in order to develop new disease ontologies, classification systems, and treatments for acute kidney injury (AKI) and chronic kidney disease (CKD). Since its inception, the KPMP has sought out and included substantive patient-representative feedback regarding disease experience, lack of innovation in new kidney disease therapies and patient tolerance for risk levels in balance with potential benefits both to the individual and society. The KPMP Has publicly and operationally committed itself to always put participants and their best interests first and this foundational principle informs and undergirds every facet of the study. Both AKI and CKD are conditions that impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. The network will utilize state-of-the-art methods to perform molecular interrogation of the tissue and to link the molecular data to kidney structure and clinical information in the form of a kidney tissue atlas. Molecular and imaging data derived from kidney tissue will be integrated with clinico-pathologic and genetic information, as well as other data derived from analyses of fluid biospecimens, including peripheral blood, urine, and stool. Using advanced analytics to integrate the data, KPMP will aim to define kidney disease subgroups in molecular terms by identifying critical cells, pathways and targets for novel therapies. Patients with AKI or CKD will be recruited from clinical care encounters (e.g., clinic visits for CKD patients, hospitalization or emergency room visits for AKI patients) and from electronic resources (e.g., existing registries, electronic health records). All study procedures are designed to optimize participant safety and will be ethically conducted, ensuring subjects fully understand the scope of the study and any possible risks. For each participant, kidney tissue will be obtained for molecular phenotyping and clinical diagnosis. The diagnostic interpretation will be returned to the participant's primary caregiver to inform clinical care, but no treatment interventions will be prescribed by the KPMP. In addition to kidney biopsy, the study will involve collection of baseline (time of biopsy) and longitudinal biospecimens (including urine, plasma, serum, DNA and stool) and demographic, clinical, and laboratory data. Participants will be followed through scheduled in-person and remote (telephone) study visits, as well as through periodic review of electronic health records.

Related studies

RECRUITING

Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients

NCT05282732 · Renal Failure, End Stage Renal Disease, and more

Active Not Recruiting

Immune Function in Acute Kidney Injury

NCT02470507 · Acute Kidney Failure

TERMINATEDPhase 3

I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus deLayed in Intensive Care Unit)

NCT01682590 · Septic Shock, Acute Renal Failure (as Defined by the "Failure" Stage of the RIFLE Classification)

COMPLETEDPhase 3

Prevention of Serious Adverse Events Following Angiography

NCT01467466 · Acute Renal Failure, Kidney Disease, and more

Not Yet RecruitingNA

SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes

NCT06926946 · Acute Renal Failure, Neonatal Morbidity

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 19, 2022Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment1,000

Start dateSep 2019

Last updatedMay 19, 2022

Condition

Acute Kidney Failure Acute Kidney Insufficiency Acute Renal Failure Acute Renal Injury Acute Renal Insufficiency+9 more

Locations shown

Yale University

New Haven, Connecticut

Johns Hopkins University

Baltimore, Maryland

Brigham & Women's Hospital

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 19, 2022Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions